Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines

Experimental Oncology

Volumn 30, Issue 2, 2008, Pages 160-162

  Pudil, R ^a   Horacek, J M ^b   Strasova, A ^a   Jebavy, L ^b   Vojacek, J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Cardiotoxicity; Echocardiography; Left ventricular diastolic dysfunction

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DAUNORUBICIN; IDARUBICIN; MITOXANTRONE;

ACUTE LEUKEMIA; ADULT; ARTICLE; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; DIASTOLE; DIASTOLIC DYSFUNCTION; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; MONITORING; SYMPTOMATOLOGY;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; DIASTOLE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART ATRIA; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; RISK FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 46749085537     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2006; 5: 791-809.
2. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, et al. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999; 25: 237-47.
3. Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity. The role of troponins and other markers. Drug Saf 2002; 25: 301-11.
4. Galderisi M, Marra F, Esposito R, Lomoriello VS, et al. Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography. Cardiovasc Ultrasound 2007; 5: 4.
5. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis and management. Circulation 2004; 109: 3122-31.
6. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003; 97: 1991-8.
7. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23: 2629-36.
8. Kmpicka J, Markova J, Pohlreich D, et al. Echocardiography evaluation of acute cardiotoxicity in the treatment of Hodgkin disease according to the German Hodgkin's Lymphoma Study Group. Leuk Lymphoma 2002; 43: 2325-9.
9. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989; 118:92-8.
10. Elbl L, Vasova I, Tomaskova I. Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma. Neoplasma 2006; 53: 174-81.
11. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58.
12. Nagy AC, Tolnay E, Nagykalnai T, Forster T. Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI. Neoplasma 2006; 53: 511-7.